Abstract Overexpression of the EGFR has been linked to cell malignancy, metastasis and poor prognosis thus making it a target for several FDA approved drugs such as Gefitinib and Erlotinib. Unfortunately, these drugs have yielded suboptimal clinical results. In order to evaluate and monitor EGFR-targeted treatment response at the molecular level, several PET biomarkers have been developed. One of the lead irreversible inhibitors (1) has been ...
[Porcari, Anthony R.; Devivar, Rodrigo V.; Kucera, Louis S.; Drach, John C.; Townsend, Leroy B. Journal of Medicinal Chemistry, 1998 , vol. 41, # 8 p. 1252 - 1262]
